International Association for the Study of Lung Cancer: Antibody-Drug Conjugate I-DXd Shows Clinically Meaningful Response in Patients With Extensive-Stage Small Cell Lung Cancer
September 09, 2024
September 09, 2024
AURORA, Colorado, Sept. 9 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release:
(San Diego, Calif.--September 7, 2024, 8:30 a.m. PDT) -- The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study. The data was presented today at the International Asso . . .
(San Diego, Calif.--September 7, 2024, 8:30 a.m. PDT) -- The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study. The data was presented today at the International Asso . . .